Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Olvimulogene nanivacirepvec by Genelux for Non-Small Cell Lung Carcinoma: Likelihood of Approval
Olvimulogene nanivacirepvec is under clinical development by Genelux and currently in Phase I for Non-Small Cell Lung Carcinoma. According to...
Olvimulogene nanivacirepvec by Genelux for Endometrial Cancer: Likelihood of Approval
Olvimulogene nanivacirepvec is under clinical development by Genelux and currently in Phase III for Endometrial Cancer. According to GlobalData, Phase...
Olvimulogene nanivacirepvec by Genelux for Ovarian Cancer: Likelihood of Approval
Olvimulogene nanivacirepvec is under clinical development by Genelux and currently in Phase III for Ovarian Cancer. According to GlobalData, Phase...